Pacer Advisors’s Cardiff Oncology CRDF Stock Holding History

Pacer Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-5,362	Closed	-$96K	–	1527
2020 Q4	$96K	Buy	+5,362	New	+$94.2K	﹤0.01%	1372

Other funds holding CRDF

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Pacer Advisors's CRDF Position: Q1 2021 in Review

Pacer Advisors sold out of Cardiff Oncology (CRDF) in Q1 2021, closing a stake of 5,362 shares — an estimated $96K sold.

Pacer Advisors first reported a position in CRDF in Q4 2020 and held it in 1 quarter. The position peaked at $96K in Q4 2020. 73 funds tracked by Wall St. Rank hold CRDF as of Q1 2021.

Pacer Advisors reported no remaining Cardiff Oncology position as of Q1 2021 after selling out during the quarter.
Pacer Advisors sold 5,362 Cardiff Oncology shares in Q1 2021, an estimated $96K.
Pacer Advisors first reported a position in Cardiff Oncology in Q4 2020 and held it in 1 quarter.
Pacer Advisors's Cardiff Oncology position peaked at $96K in Q4 2020.
73 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2021.

Based on Pacer Advisors's 13F filing for Q1 2021, filed 5 Apr 2021.